Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : LLY crawled date : 2022 - 05 - 11 save search
FDA Approves Lilly and Incyte's Olumiant For Hospitalized COVID-19 Patients
Published: 2022-05-11 (Crawled : 16:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
covid-19 fda olumiant
FDA Approves Eli Lily's Olumiant For Hospitalized COVID-19 Patients
Published: 2022-05-11 (Crawled : 16:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
covid-19 fda olumiant covid
The PCSK9 Inhibitors Market to Grow Rapidly During the Forecast Period with a CAGR of 15.1%, Analyzes DelveInsight
Published: 2022-05-11 (Crawled : 15:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.33%
H: 0.0%
C: 0.0%
market
Artax Biopharma Closes Financing to Advance Clinical Stage First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases
Published: 2022-05-11 (Crawled : 12:20) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
biopharma disease
Heart Failure Treatment Offers Hope to Diabetics
Published: 2022-05-11 (Crawled : 12:00) - prnewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -2.55%
H: 2.32%
C: -0.85%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.33%
H: 0.0%
C: 0.0%
treatment heart
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19
Published: 2022-05-11 (Crawled : 11:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 2.48%
H: 1.15%
C: -2.43%
covid-19 olumiant treatment fda
FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients
Published: 2022-05-11 (Crawled : 11:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 20.75%
H: 0.0%
C: 0.0%
covid-19 fda sabizabulin authorization positive phase 3 emergency use authorization
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.